soul trial oral semaglutide cardiovascular outcomes 2024 nejm results Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results Oral Semaglutide and Cardiovascular Outcomes

Frequently Asked Questions Glossary References Davis SR, Castelo-Branco C, Chedraui P, et al

Current evidence suggests semaglutide does not have significant immunosuppressive or immunostimulatory properties that would substantially alter autoimmune disease course

A dedicated screen is harder for a patient to race past than an item deep inside a long multi-select, and it puts the black-box warning front-and-center in a way that matches how the actual prescribing information treats it

It is also used for cardiovascular risk reduction, kidney disease, and off-label for weight management

Each prescription determination is made independently by a Novi licensed clinician following an individual medical consultation

Abstract Purpose of Review Moderate hypertriglyceridemia is exceedingly common in diabetes, and there is growing evidence that it contributes to residual cardiovascular risk in statin-optimized patients